Conference abstractPublished 2021

Rituximab Associated Cellulitis: Pharmacovigilance Signal Review

Authors: Turki Zaid Alozayb

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Rituximab is a chimeric mouse/human monoclonal antibody that is indicated primarily for the treatment of Non-Hodgkin’s lymphoma (NHL). Rituximab cell destruction activity is mediated via binding to surface antigen CD20 inducing signaling of apoptosis, complement activation, and cell-mediated cytotoxicity. Cellulitis is an infection of the skin. Patients with cellulitis for the most part present with agonizing, hot, and swollen skin. The reason for this review is to assess the risk of Cellulitis related to Rituximab use and to propose regulatory recommendations whenever required. On Aug 18, 2021, we performed a signal review utilizing World Health Organization (WHO) VigiBase, with literature screening to recover all related information to assess the causality between Cellulitis and Rituximab use. Causality assessment was done according to the WHO-UMC system for standardized case causality assessment. The disproportionality of the observed and the expected reporting rate for the Rituximab/Cellulitis pair is estimated using the information component (IC). Positive IC values reflect higher statistical association while negative values indicate less statistical association. The review resulted in 57 Individual Case Safety Reports (ICSRs). Out of 42 assessable ICSRs, 3 cases revealed probable association, and 25 cases revealed a possible association between Rituximab use and risk of Cellulitis. IC value of (1.1) revealed a positive statistical association. The weighted cumulative evidence identified from cases is sufficient to validate and suggest a causal association between Rituximab and Cellulitis. Therefore, health care professionals should be aware of this potential risk and may consider monitoring any signs or symptoms of Cellulitis in patients treated with Rituximab.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in International Journal of Drug Development and Research.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Drug Development and Research
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Turki Zaid Alozayb”